Institute of Translational Medicine.
Department of Hepatology, the First Hospital of Jilin University, Changchun, Jilin province, China.
Medicine (Baltimore). 2020 Dec 11;99(50):e23659. doi: 10.1097/MD.0000000000023659.
This study was aimed to evaluate the association between interleukin-6 (IL-6) gene polymorphisms and the risk of hepatocellular carcinoma (HCC) in a meta-analysis.
A literature search was performed for case-control studies published during May, 1993 to May, 2020 focusing on IL-6 gene polymorphisms (-174G > C, -572G > C, and -597G > A) and HCC susceptibility by using PubMed, Cochrane Database, EMBASE, Web of science, and China National Knowledge Infrastructure. From 128 full-text articles, 11 were included in this meta-analysis. I index was used to assess heterogeneity and Newcastle-Ottawa Scale was utilized for quality assessment.
For IL-6 -174G > C polymorphism, in codominant (GG vs CC: odds ratios [OR] = 2.78, 95% confidence intervals [CI] = 1.25-6.19, P = .01, I = 16%) and recessive (GG+GC vs CC: OR = 2.76, 95% CI = 1.29-5.90, P = .009, I = 3%) models, IL-6 -174G>C polymorphism was significantly associated with the risk of HCC. In dominant (GG vs CC+GC: OR = 1.80, 95% CI = 0.92-3.54, P = .09, I = 86%) and allele (G vs C: OR = 1.49, 95% CI = 0.95-2.32, P = .08, I = 68%) models, IL-6 -174G>C polymorphism had no impact on the risk of HCC. However, in non-Italian Caucasian population, IL-6 -174G>C polymorphism was significantly related to the occurrence of HCC in both dominant (GG vs CC+GC: OR = 3.26, 95% CI = 2.29-4.65, P < .00001, I = 0%) and allele (G vs C: OR = 2.48, 95% CI = 1.48-4.15, P = .0006) models. Such correlations also could be observed when healthy individuals were selected as controls. For IL-6 -572G>C and -597G>A polymorphisms, no significant association was observed in all models, regardless of the source of control and population subgroups. No publication bias could be calculated when Begg and Egger tests were employed.
This meta-analysis indicated that IL-6 -174G>C polymorphism was significantly related with the risk for HCC, especially in non-Italian Caucasian population. No significant association was observed for the correlation between IL-6 -572G>C and -597G>A polymorphisms and HCC susceptibility.
本研究旨在通过荟萃分析评估白细胞介素 6(IL-6)基因多态性与肝细胞癌(HCC)风险之间的关联。
通过使用 PubMed、Cochrane 数据库、EMBASE、Web of Science 和中国国家知识基础设施,对 1993 年 5 月至 2020 年 5 月期间发表的关于 IL-6 基因多态性(-174G > C、-572G > C 和 -597G > A)与 HCC 易感性的病例对照研究进行了文献检索。从 128 篇全文文章中,有 11 篇被纳入本荟萃分析。使用 I 指数评估异质性,使用纽卡斯尔-渥太华量表评估质量。
对于 IL-6 -174G > C 多态性,在共显性(GG 与 CC:比值比 [OR] = 2.78,95%置信区间 [CI] = 1.25-6.19,P = 0.01,I = 16%)和隐性(GG+GC 与 CC:OR = 2.76,95%CI = 1.29-5.90,P = 0.009,I = 3%)模型中,IL-6 -174G > C 多态性与 HCC 风险显著相关。在显性(GG 与 CC+GC:OR = 1.80,95%CI = 0.92-3.54,P = 0.09,I = 86%)和等位基因(G 与 C:OR = 1.49,95%CI = 0.95-2.32,P = 0.08,I = 68%)模型中,IL-6 -174G > C 多态性与 HCC 风险无关。然而,在非意大利白种人群中,IL-6 -174G > C 多态性在显性(GG 与 CC+GC:OR = 3.26,95%CI = 2.29-4.65,P < 0.00001,I = 0%)和等位基因(G 与 C:OR = 2.48,95%CI = 1.48-4.15,P = 0.0006)模型中与 HCC 的发生显著相关。当选择健康个体作为对照时,也可以观察到这种相关性。对于 IL-6 -572G > C 和 -597G > A 多态性,在所有模型中均未观察到显著关联,无论对照的来源和人群亚组如何。当使用 Begg 和 Egger 检验时,无法计算发表偏倚。
本荟萃分析表明,IL-6 -174G > C 多态性与 HCC 风险显著相关,尤其是在非意大利白种人群中。IL-6 -572G > C 和 -597G > A 多态性与 HCC 易感性之间无显著相关性。